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AbstrACt
Objectives To assess evidence for ‘legacy’ (post-trial) 
effects on cardiovascular disease (CVD) mortality and 
all-cause mortality among adult participants of placebo-
controlled randomised controlled trials (RCTs) of statins.
Design Meta-analysis of aggregate data.
setting/Participants Placebo-controlled statin RCTS for 
primary and secondary CVD prevention.
Methods Data sources: PubMed, Embase from inception 
and forward citations of Cholesterol Treatment Trialists’ 
Collaborators RCTs to 16 June 2016. Study selection: Two 
independent reviewers identified all statin RCT follow-up 
reports including ≥1000 participants, and cardiovascular 
and all-cause mortality. Data extraction and synthesis: 
Two independent reviewers extracted data in accordance 
with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines. Main outcomes: Post-trial 
CVD and all-cause mortality.
results We included eight trials, with mean post-trial 
follow-up ranging from 1.6 to 15.1 years, and including 
13 781 post-trial deaths (6685 CVD). Direct effects of 
statins within trials were greater than legacy effects post-
trials. The pooled data from all eight studies showed no 
evidence overall of legacy effects on CVD mortality, but 
some evidence of legacy effects on all-cause mortality 
(p=0.01). Exploratory subgroup analysis found possible 
differences in legacy effect for primary prevention trials 
compared with secondary prevention trials for both CVD 
mortality (p=0.15) and all-cause mortality (p=0.02). Pooled 
post-trial HR for the three primary prevention studies 
demonstrated possible post-trial legacy effects on CVD 
mortality (HR=0.87; 95% CI 0.79 to 0.95) and on all-cause 
mortality (HR=0.90; 95% CI 0.85 to 0.96).
Conclusions Possible post-trial statin legacy effects on 
all-cause mortality appear to be driven by the primary 
prevention studies. Although these relative benefits were 
smaller than those observed within the trial, the absolute 
benefits may be similar for the two time periods. Analysis 
of individual patient data from follow-up studies after 
placebo-controlled statin RCTs in lower-risk populations 
may provide more definitive evidence on whether early 
treatment of subclinical atherosclerosis is likely to be 
beneficial.
IntrODuCtIOn 
‘Legacy effects’ are treatment effects that 
persist or emerge at some time after trial 
treatment ends. The existence, or not, of such 
legacy effects have important clinical implica-
tions, including the potential value of starting 
preventative treatment at a younger age, and 
the risks of treatment cessation. Although 
technically even short-term or transient 
improvement or worsening of symptoms and 
signs may be classified as a legacy effect, most 
people appear to use the term to indicate 
sustained clinical benefit or harm.1–7 Legacy 
effects have been explained as the ‘memory 
of a treatment given in an early phase of a 
disease which produces benefits long after 
the cessation of intervention’.2 They are an 
extension of the belief that we should inter-
vene with treatment early on in the course of 
a chronic disease/condition; the legacy effect 
assumes that the duration of the condition 
predicts permanent pathological changes 
which in turn are strong modifiers of treat-
ment effectiveness.
Recently, there has been considerable 
interest in the possible legacy effects of 
statins,8 9 sparked by reports on the long-
term outcomes for participants of large 
placebo-controlled trials. In some of these 
strengths and limitations of this study
 ► Our sensitive search strategy means this study 
is likely to have included all follow-up reports of 
the major placebo-controlled statin trials, includ-
ing recent follow-up reports for two of the studies 
(WOSCOPS and LIPID).
 ► We focus analysis on the post-trial period which is 
best for detection of legacy effects.
 ► However, post-trial data are no longer a randomised 
comparison, and legacy effects may be larger than 
we estimated.
 ► The main limitation is that our findings are based on 
aggregate data, and we did not have information on 
whether or not an individual was treated with statins 
during the post-trial period, and for how long, as well 
as their cardiovascular risk factor levels and other 
potential confounders.
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reports,4 10 there is still a persistent survival advantage to 
participants who were randomised to statin during the 
trial, even though there was no or minimal difference 
in the management of participants after the trial ended. 
Legacy effects could indicate that earlier treatment with 
statins slows atherosclerotic plaque build-up in arteries 
and so alters the natural disease progression during a 
person’s lifetime. As with the direct effects of statins, these 
legacy effects may be pleiotropic, and act through anti-in-
flammation, anticoagulation and/or lipid lowering. This 
hypothesis has some support from the finding that statins 
have minimal effect on cardiovascular disease (CVD) 
prevention in patients with advanced kidney disease who 
require haemodialysis, and who have high short-term risk 
of CVD,11 but reduce CVD events in patients with earlier 
chronic kidney disease who are not yet requiring haemo-
dialysis.12 There are also some data from a small imaging 
study of patients with angina to support the early treat-
ment hypothesis, where similar reduction in lipid levels 
appeared to result in reduction in plaque volume only in 
participants younger than 65 years.13 Finally, differences 
in long-term response to statins are noted for primary 
prevention trials compared with secondary prevention 
trials.14 To this end, aggressive lipid-lowering therapy in 
much younger individuals with lower risk for CVD has 
been suggested as a possible means of primary preven-
tion. Some have argued for universal screening of choles-
terol levels in young people and offering early statin 
treatment to those with raised levels,15–17 whereas others 
have argued that statins be offered to all young people, 
regardless of cholesterol levels.5 18
At least some of the survival benefit observed on long-
term follow-up is attributable to the direct treatment 
effects on CVD outcomes observed during the with-
in-trial period. To illustrate this point, we generated data 
to simulate the situation where there was a legacy effect 
(see online supplementary eFigure 1A and 1 B), and 
where there was not a legacy effect (online supplementary 
eFigure 1C and 1D). We simulated two scenarios where 
an intervention has effects during the trial period, and 
either (1) has an additional effect after the trial (legacy 
effect) or (2) has no additional effect after the trial (no 
legacy effect). In the survival curves of both scenarios, the 
apparent legacy effect is exaggerated because the cumula-
tive incidence includes the direct effects during the initial 
trial period (see online supplementary eFigure 1A and 
1C). If hazard curves are constructed instead, the direct 
effects during the initial trial period are not included 
in the instantaneous hazard of the post-trial periods, 
allowing an unbiased estimation of the legacy effect 
(see online supplementary eFigure 1B and 1D; note that 
these are curves of the instantaneous hazard at each time 
point, and are not curves of hazard ratios (HRs). Details 
of the methods for the simulation are provided in the 
Appendix). Although survival curves like online supple-
mentary eFigure 1A and 1C demonstrate that the direct 
effects of the intervention (observed during the trial 
period) are still apparent many years later, they do not 
provide evidence of legacy effects after the intervention 
has ceased. From the hazard curves in online supplemen-
tary eFigure 1B and 1D, it is clear that to estimate legacy 
effects, we should instead focus on outcomes observed 
during the post-trial period. To this end, we aimed to iden-
tify and combine estimates of the effect of trial treatment 
group allocation on post-trial all-cause and CVD mortality 
from published reports on the long-term follow-up after 
placebo-controlled trials of statins.
MethODs
Protocol and registration
The review protocol was not registered.
selection
We performed a systematic search and meta-analysis of all 
reports on follow-up after randomised, placebo-controlled 
studies of adults (age >18 years) of statins with ≥1000 
participants. As the legacy effect relates to the difference 
in treatment received within the trial period, we focused 
our analysis on follow-up reports of high-quality, large 
randomised controlled trials (RCTs). We chose to limit 
our studies to those with ≥1000 participants in the orig-
inal trial for consistency with the Cholesterol Treatment 
Trialists’ Collaboration. These large trials were designed 
to assess effects on mortality within the trial period, and 
their follow-up reports are the most appropriate studies 
to address post-trial effects on mortality. We excluded 
studies that did not report mortality data during post-
trial follow-up. The primary outcomes were death due to 
all-causes and death due to CVD.
search strategy
We identified placebo-controlled RCTs of cholesterol-low-
ering treatment from the Cholesterol Treatment Trial-
ists’ Collaboration19 and ran forward citation searches in 
Scopus; our search was limited to those citations which 
included one of the investigators from the RCT. We 
searched for additional reports in Medline and Embase 
with no earliest date restriction, though to 16 June 2016 
using the terms listed in box 1, with no restrictions on 
year published, type of publication or language. We 
checked references of included studies to identify further 
relevant papers and contacted trialists to identify updated 
or additional reports.
box 1 search terms for Medline search
1. Follow-Up Studies/
2. random$.tw
3.  placebo. tw
4. Hydroxymethylglutaryl-CoA Reductase Inhibitors/
5. cholesterol/
6. lipids/
7. (#1) AND (#2) AND (#3) AND (#4 OR #5 OR #6).
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Figure 2 Direct (within-trial) and legacy (post-trial) effects of statins on all-cause mortality for eight trials. Note: Within primary 
and secondary prevention subgroups, studies are ordered by duration of follow-up.
Figure 1 Direct (within-trial) and legacy (post-trial) effects of statins on cardiovascular disease mortality for eight trials. Note: 
Within primary and secondary prevention subgroups, studies are ordered by duration of follow-up.
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Figure 3 Random effects meta-analysis of relative risks for legacy (post-trial) effects of statins on cardiovascular disease 
mortality for eight trials. Note: Within primary and secondary prevention subgroups, studies are ordered by duration of follow-
up. RR, relative risk.
Figure 4 Random effects meta-analysis of relative risks for legacy (post-trial) effects of statins on all-cause mortality for eight 
trials. Note: Within primary and secondary prevention subgroups, studies are ordered by duration of follow-up. RR, relative risk.
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Validity assessment
Two authors (AN and LZ) extracted data on the following 
characteristics which may bias the estimated legacy effect: 
mean follow-up (years) and difference in proportion 
taking statins. Data were extracted separately for the 
within trial and post trial periods for each study. 
study selection and data abstraction
Two authors (AN and KB) independently checked the 
titles and abstracts of all citations identified through 
the database searches and forward citation search. Full 
text was obtained if either author judged the article 
potentially relevant. The same two authors then inde-
pendently checked all the full-text articles for eligibility, 
resolving disagreements through discussion.
Two authors independently extracted clinical data (AN 
and LZ) using standardised forms, deciding disagree-
ments through discussion with a third author (KB). We did 
not calculate formal measures of agreement to describe 
agreement between reviewers. The Cochrane Collabora-
tion recommends against doing this, and instead recom-
mends exploring reasons for any disagreement early on 
in the review process,20 which we did through discussion. 
Figure 5 Random effects meta-analysis of HR for legacy (post-trial) effects of statins on cardiovascular disease mortality for 
four trials. Note: Within primary and secondary prevention subgroups, studies are ordered by duration of follow-up.
Figure 6 Random effects meta-analysis of HR for legacy (post-trial) effects of statins on all-cause mortality for four trials. Note: 
Within primary and secondary prevention subgroups, studies are ordered by duration of follow-up.
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We extracted separate data on all-cause mortality and 
CVD-specific mortality for the within-trial and post-trial 
periods; the number of people at risk of each type of 
event at the start of the trial and at the start of the post-
trial follow-up; the proportion of people taking statins 
within trial and post-trial; and the duration of follow-up 
within trial and post-trial. We attempted to extract differ-
ences in mean total cholesterol, but these were missing 
for at least one of the periods in the majority of studies. 
Further data on the original trials were obtained from 
Cholesterol Treatment Trialists Collaboration (CTTC).21
statistical methods
Summary statistics and plots for individual trials were 
generated using SAS V.9.4.
Meta-analytic models of post-trial data were built using 
STATA (V.14.2).
We built meta-analytic models for CVD mortality and 
all-cause mortality using reported number of events and 
number at risk for the post-trial period. Our principal 
summary measures for the models were relative risk and 
HR. We used adjusted relative risks where these were 
Figure 7 Random effects meta-analysis of HR for legacy (post-trial) effects of statins on cardiovascular disease mortality for 
three primary prevention trials. Note: Within primary and secondary prevention subgroups, Studies are ordered by duration of 
follow-up.
Figure 8 Random effects meta-analysis of HR for legacy (post-trial) effects of statins on all-cause mortality for three primary 
prevention trials. Note: Within primary and secondary prevention subgroups, Studies are ordered by duration of follow-up.
 o
n
 30 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020584 on 4 October 2018. Downloaded from 
8 Nayak A, et al. BMJ Open 2018;8:e020584. doi:10.1136/bmjopen-2017-020584
Open access 
reported, and calculated unadjusted relative risks where 
they were not. We built random effects models for the 
analysis. We assessed the hetereogeneity of results using 
visual inspection of forest plots and I2 statistics, and we 
conducted exploratory subgroup analysis using meta-re-
gression to compare primary and secondary preven-
tion trials. For the subgroup analysis, we tested for 
subgroup differences using a permutation test with 1000 
permutations.22
We also built HR meta-analytic models for CVD mortality 
and all-cause mortality where these were reported in the 
primary studies. We undertook sensitivity analysis by 
restricting the model to primary prevention trials.
Patient and public involvement
Patients and or public were not involved in this meta-anal-
ysis of published data.
results
We identified 21 placebo-controlled RCTs of statins 
included in the CTTC for forward citation searching23–43 
which retrieved 1520 abstracts (restricting search to 
reports which included an original trialist as an author). 
We identified a further 828 abstracts from Medline and 
Embase (searches to 16 June 2016), and after excluding 
duplicates, 1520 titles and abstracts were screened. We 
retrieved 61 papers for full-text review, 47 of which did 
not meet our selection criteria (see online supplemen-
tary eFigure 2). Reference searching of the remaining 
14 studies identified one further study. Seven of the 15 
studies used overlapping data: for each set of potentially 
overlapping reports, we chose the most recent report. 
This resulted in eight studies finally included in our 
review (table 1).
The original RCTs ranged in mean duration from 3.2 to 
5.2 years, included trials of simvastatin, pravastatin, fluvas-
tatin and atorvastatin, and their primary results were 
published between 1994 and 2003. Of the randomised 
participants in each trial, 0% to 52% were women, the 
mean age ranged from 50 to 75 years and 1% to 35% were 
diabetic. Between 8% and 100% had pre-existing CVD: 
three predominantly primary prevention/asymptomatic 
populations, and five predominantly secondary preven-
tion/symptomatic populations. The difference in the 
proportion of people taking a statin in the randomised 
groups within the trial period (statin—placebo) ranged 
from 51% to 89%. HR (or relative risk ratio estimates when 
HR were unknown) for all-cause mortality and CVD-spe-
cific mortality within the trial period ranged from 0.70 to 
1.02 and 0.64 to 0.96, respectively (see online supplemen-
tary eTable 1).
The post-trial follow-up ranged in mean duration 
from 1.6 to 15.1 years. The difference in proportion of 
people taking a statin in the post-trial period (for those 
originally randomised to statin minus those randomised 
to placebo) ranged from 0% to 4% (unknown for two 
studies). Collectively, the included studies reported on 
post-trial follow-up of 55 732 people with 13 781 deaths 
which occurred after the trials ended, of which 6685 
were attributed to CVD. The HR (or relative risk esti-
mates) for all-cause mortality and CVD-specific mortality 
ranged from 0.85 to 1.03 and 0.82 to 1.14, respectively 
(see online supplementary eTable 2).
Individual trials: comparison of within-trial and post-trial 
effects
The results for CVD-specific mortality for the individual 
trials are presented in supplementary eTable 1 and 2 and 
figure 1. Of the eight included trials, the six which demon-
strated significant reductions in CVD mortality within the 
trial period (WOSCOPS, ALERT, SSSS, PROSPER, HPS 
and LIPID) showed less benefit in the post-trial period 
than in the trial period. The two trials without signifi-
cant reduction in CVD mortality within the trial period 
(ALLHAT-LLA and ASCOT-LLA) showed a similar lack 
of evidence for benefit post-trial. In only one of the eight 
trials was there a significant reduction in CVD mortality 
for the post-trial period (WOSCOPS).
The results for all-cause mortality for the individual trials 
are presented in online supplementary eTables 1 and 2 
and figure 2. Of the eight included trials, the four which 
demonstrated significant reduction in all-cause mortality 
within the trial period (WOSCOPS, SSSS, HPS and 
LIPID) showed less benefit in the post-trial period than in 
the trial period. Three trials without a significant reduc-
tion in mortality within the trial period (ALLHAT-LLA, 
ALERT and PROSPER) showed a similar lack of evidence 
for benefit post-trial. One trial (ASCOT-LLA) without a 
significant reduction in mortality within the trial period 
demonstrated more benefit in the post-trial period. In 
only two of the eight trials was there a significant reduction 
in all-cause mortality in the post-trial period (WOSCOPS 
and ASCOT-LLA).
Post-trial meta-analysis
The relative risk random effect meta-analysis using post-
trial data from all eight studies is presented in figure 3 
(CVD mortality) and figure 4 (all-cause mortality). 
Although there was no evidence overall of a post-trial 
(legacy) effect on CVD (p=0.15), there was some evidence 
of a legacy effect on all-cause mortality (p=0.01). In the 
exploratory subgroup analysis, there appeared to be a 
difference in the post-trial (legacy) effect of statins for 
primary prevention compared with secondary preven-
tion studies for both CVD and for all-cause mortality. 
The pooled relative risk of CVD death post-trial for those 
originally allocated statin compared with placebo was 
0.91 (0.84–0.98) for primary prevention trials, and 0.99 
(0.94–1.05) for secondary prevention trials (permutation 
test p value for subgroup difference=0.15) (figure 3). The 
pooled relative risk of all-cause death post-trial for those 
originally allocated statin compared with placebo was 
0.92 (0.88–0.96) for primary prevention trials and 0.99 
(0.95–1.03) for secondary prevention trials (permutation 
test p value for subgroup difference=0.02) (figure 4).
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The HR meta-analysis, using post-trial data from the 
four studies reporting HR, is presented in figure 5 (CVD 
mortality) and figure 6 (all-cause mortality). Similar to 
the meta-analysis of relative risks, there was no definite 
evidence of a post-trial (legacy) effect on CVD (p=0.09), 
but some evidence of a legacy effect on all-cause mortality 
(p=0.02). Pooling data from all four studies resulted in 
substantial heterogeneity between studies (I2=40.7% 
for CVD mortality and 42.3% for all-cause mortality). 
Restricting meta-analysis to the three primary preven-
tion trials resulted in very low heterogeneity between 
studies (I2=0.0% for CVD mortality and 8.1% for all-cause 
mortality), and these results are presented in figure 7 
(CVD mortality) and figure 8 (all-cause mortality). In 
the three primary prevention trials, the pooled HR for 
CVD death post-trial for those originally allocated statin 
compared with placebo was 0.87 (0.79 to 0.95, p=0.003), 
and for all-cause death, it was 0.90 (0.85 to 0.96, p=0.001).
DIsCussIOn
We identified eight large randomised trials which 
had usable post-trial data to assess legacy effects on 
mortality outcomes. The direct effects of the statins on 
mortality reduction observed during the trials were 
much larger than potential legacy effects observed post-
trial, which suggests the rhetoric on legacy effects for 
statins in general may not reflect the empirical evidence. 
WOSCOPS was the only trial to show a possible post-trial 
legacy effect on all-cause and CVD-specific mortality. 
When we pooled data from all eight studies, we found 
no evidence overall of legacy effects on CVD mortality, 
but some evidence of possible legacy effects on all-cause 
mortality. In the exploratory subgroup analysis, there 
was some evidence of a difference in results for primary 
prevention compared with secondary prevention. Consid-
ering these subgroups separately, we found no evidence 
of legacy effects following secondary prevention trials, 
suggesting the importance of long-term/lifelong preven-
tion in these patients. We found evidence of possible 
post-trial legacy effects only when statins were started 
for primary prevention—these effects were observed on 
both CVD mortality (HR=0.87, p=0.003) and all-cause 
mortality (HR=0.90, p<0.001) (figure 3C,D). Participants 
originally randomised to placebo in two of the primary 
prevention trials (WOSCOPS and ASCOT-LLA) had 4% 
lower rates of using a statin in the first years post-trial, 
which will exaggerate the estimated legacy effect (bias 
away from the null), but this difference is unlikely to 
account for all the observed post-trial benefit (whether 
there was a difference in statin use post-trial in ALLHAT 
is not known). The observed post-trial reductions in CVD 
and all-cause mortality may potentially represent real 
legacy effects of statins for populations similar to those at 
the time of recruitment into these studies. There may be 
a higher likelihood of observing legacy effects for statins 
when this is started for primary prevention, rather than 
for secondary prevention.
Our sensitive search strategy means this study is likely 
to have included all published follow-up reports of the 
major placebo-controlled statin trials, including recent 
follow-up reports for two of the studies (WOSCOPS and 
LIPID). However, we did not assess for publication bias 
and it is possible that unpublished follow-up reports may 
exist that we are unaware of. We did not assess risk of 
bias for the included studies, but this has been assessed 
by others for the original trial reports, including very 
recently,44 and the included studies were generally found 
to be high quality. Although we believe the post-trial 
period is the best period to analyse for detection of legacy 
effects, these data are no longer a randomised compar-
ison: some patients randomised to the statin would have 
been saved from dying, whereas some patients in the 
placebo group were not. Hence, there are additional 
survivors in the statin group at the beginning of post-trial 
follow-up who are also likely to be at higher risk of CVD 
than survivors in the placebo group. These differences 
would tend to bias our results towards the null, and mean 
that legacy effects may be larger than we estimated. The 
main limitation of our report is that because our findings 
are based on aggregate data, we are unable to assess the 
effects of whether or not an individual was treated with 
statins during the post-trial period, and for how long, as 
well as their cardiovascular risk factor levels and other 
potential confounders. For example, although we found 
evidence of possible legacy effects in primary prevention, 
these are largely driven by WOSCOPs which was under-
taken in all male participants. If there are sex-specific 
effects for legacy effects, it may be the fact that all partic-
ipants in WOSCOPS were male, and not that they had 
no history of CVD, that is the more important determi-
nant. Similarly, participants in WOSCOPS had the lowest 
percentage taking statins in the post-trial period out of 
all the studies where this was measured (39% of active 
and 35% of placebo participants were taking statins at 
5 years post-trial). This comparative absence of direct 
statin treatment effects in the post-trial period may be 
the more important determinant for observing a legacy 
effect.
We did not examine evidence of possible legacy effects 
on other outcomes such as non-fatal CVD, or for different 
post-trial follow-up times within each study, or for the 
same post-trial follow-up times between studies. We are 
aware of four other meta-analyses of data from long-term 
follow-up after placebo-controlled trials of lipid-low-
ering treatment.45–48 In three of these reports, the focus 
appears to have been on persistence of survival benefit, 
with comparison of event rates from time of randomisa-
tion, rather than post-trial legacy effect.45 47 48 The other 
meta-analysis reported separate results for the post-trial 
period using data from earlier follow-up reports of six of 
our included trials.46 That report found evidence of post-
trial reduction in CVD mortality and all-cause mortality 
at 2 years, and evidence for a reduction in major coro-
nary events at both 2 years and over the total post-trial 
periods. The authors did not explore possible causes of 
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heterogeneity for the post-trial models such as whether 
the primary trial was for primary or secondary prevention.
Published trial evidence supports the hypothesis that 
lowering cholesterol with a statin drug reduces cardiovas-
cular events.49 Currently, the principle of using absolute 
risk to guide treatment decisions (as recommended by 
guidelines50–53) is that treatment is prioritised for those at 
highest short-term risk, and people at low short-term risk 
are not treated. Data on the efficacy and safety of statins 
has led to treatment thresholds being lowered: in the UK, 
the threshold was lowered from >20% to >10% 10-year risk 
of CVD; in the USA, the threshold is 10% 10-year risk of 
CVD, with statins also recommended for selected patients 
with 7.5%–10% 10-year risk.53 However, as short-term risk 
is largely driven by age, younger people are unlikely to 
qualify for statins even with these lowered thresholds. For 
example, a recent report found that in the absence of 
smoking or raised blood pressure, a 10-year risk of CVD 
above 5% was infrequent in women younger than 50 and 
men younger than 40 years resident in the USA.54
Exploratory subgroup analysis in our study found 
evidence of possible legacy effects of statins following 
the primary prevention trials, which warrant further 
investigation. However, we note that the participants in 
WOSCOPS, ALLHAT and ASCOT-LLA had elevated 
levels of CVD risk factors (see table 1). Indeed, the 
majority of these people were likely to have been well 
above current treatment thresholds at the time of trial 
entry, and people with similar risk levels would now be 
recommended to start lifelong lipid-lowering treatment. 
For example, the proportion of people who had died of 
CVD by the end of the trial in the placebo group after 
3.3 years in ASCOT, 4.8 years in ALLHAT and 4.9 years 
in WOSCOPS was 3%, 11% and 2%, respectively. Legacy 
effects in these settings serve to emphasise the benefits 
of starting long-term primary prevention treatment early 
rather than later among people at high short-term risk. 
It does not provide evidence to support earlier treatment 
for people who have lower short-term risk than current 
treatment thresholds.
Advocates of early intervention argue that people 
who are at risk of disease in the long term, but currently 
displaying no symptoms or signs of disease and at low 
calculated short-term risk, should also be started on long-
term treatment at an early age.5 18 But deciding when, and 
if, to intervene in these people is much less straightfor-
ward. The legacy effect hypothesis for statins—that the 
earlier you start, the lower your risk of a CVD event in 
the long term—has not been tested directly in an RCT 
comparing statins commencement at an earlier versus 
later age, and such a trial is unlikely to eventuate. Indirect 
evidence from post-trial follow-up after the large statin 
trials is likely the next best way to investigate this.
COnClusIOn
In this analysis of eight long-term randomised trials, we 
found possible post-trial legacy effects of statins on CVD 
mortality and all-cause mortality for primary prevention. 
Although the post-trial relative benefits were clearly 
smaller than those observed within trials, the increasing 
risk with age may mean that the absolute benefits are 
similar. Analysis of individual patient data from follow-up 
studies after placebo-controlled RCTs in lower-risk popu-
lations may provide more definitive evidence on whether 
early treatment of subclinical atherosclerosis is likely to 
be beneficial.
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